TY - JOUR
T1 - Therapeutic potential of HIV-1 entry inhibitor peptidomimetics
AU - Korie, Nneka P.U.
AU - Tandoh, Kwesi Z.
AU - Kwofie, Samuel K.
AU - Quaye, Osbourne
N1 - Publisher Copyright:
© 2021 by the Society for Experimental Biology and Medicine.
PY - 2021/5
Y1 - 2021/5
N2 - Human immunodeficiency virus 1 (HIV-1) infection remains a public health concern globally. Although great strides in the management of HIV-1 have been achieved, current highly active antiretroviral therapy is limited by multidrug resistance, prolonged use-related effects, and inability to purge the HIV-1 latent pool. Even though novel therapeutic options with HIV-1 broadly neutralizing antibodies (bNAbs) are being explored, the scalability of bNAbs is limited by economic cost of production and obligatory requirement for parenteral administration. However, these limitations can be addressed by antibody mimetics/peptidomimetics of HIV-1 bNAbs. In this review we discuss the limitations of HIV-1 bNAbs as HIV-1 entry inhibitors and explore the potential therapeutic use of antibody mimetics/peptidomimetics of HIV-1 entry inhibitors as an alternative for HIV-1 bNAbs. We highlight the reduced cost of production, high specificity, and oral bioavailability of peptidomimetics compared to bNAbs to demonstrate their suitability as candidates for novel HIV-1 therapy and conclude with some perspectives on future research toward HIV-1 novel drug discovery.
AB - Human immunodeficiency virus 1 (HIV-1) infection remains a public health concern globally. Although great strides in the management of HIV-1 have been achieved, current highly active antiretroviral therapy is limited by multidrug resistance, prolonged use-related effects, and inability to purge the HIV-1 latent pool. Even though novel therapeutic options with HIV-1 broadly neutralizing antibodies (bNAbs) are being explored, the scalability of bNAbs is limited by economic cost of production and obligatory requirement for parenteral administration. However, these limitations can be addressed by antibody mimetics/peptidomimetics of HIV-1 bNAbs. In this review we discuss the limitations of HIV-1 bNAbs as HIV-1 entry inhibitors and explore the potential therapeutic use of antibody mimetics/peptidomimetics of HIV-1 entry inhibitors as an alternative for HIV-1 bNAbs. We highlight the reduced cost of production, high specificity, and oral bioavailability of peptidomimetics compared to bNAbs to demonstrate their suitability as candidates for novel HIV-1 therapy and conclude with some perspectives on future research toward HIV-1 novel drug discovery.
KW - HIV-1 novel drug discovery
KW - Human immunodeficiency virus 1
KW - antiretroviral therapy
KW - broadly neutralizing antibodies
KW - entry inhibitors
KW - peptidomimetics
UR - http://www.scopus.com/inward/record.url?scp=85101280012&partnerID=8YFLogxK
U2 - 10.1177/1535370221990870
DO - 10.1177/1535370221990870
M3 - Review article
C2 - 33596698
AN - SCOPUS:85101280012
SN - 1535-3702
VL - 246
SP - 1060
EP - 1068
JO - Experimental Biology and Medicine
JF - Experimental Biology and Medicine
IS - 9
ER -